Detalhe da pesquisa
1.
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
Br J Clin Pharmacol;
88(2): 846-852, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34265100
2.
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Br J Clin Pharmacol;
88(10): 4573-4584, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35466438
3.
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance.
Br J Clin Pharmacol;
88(3): 1010-1019, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34416045
4.
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.
Br J Clin Pharmacol;
88(5): 2284-2296, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34532877
5.
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Invest New Drugs;
35(5): 576-588, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28424891
6.
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
BMC Cancer;
17(1): 173, 2017 03 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28264648
7.
In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.
Clin Transl Sci;
17(3): e13714, 2024 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38477045
8.
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Clin Pharmacol Ther;
115(2): 349-360, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38010260
9.
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
Mol Cancer Ther;
22(5): 679-690, 2023 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36888921
10.
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Invest New Drugs;
35(5): 669, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28676972
11.
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
Clin Pharmacol Drug Dev;
11(11): 1294-1307, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36029150
12.
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
BMC Clin Pharmacol;
11: 3, 2011 Mar 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21414193
13.
Imputing Biomarker Status from RWE Datasets-A Comparative Study.
J Pers Med;
11(12)2021 Dec 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34945827
14.
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019.
J Clin Pharmacol;
61(8): 1106-1117, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33624833
15.
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
J Clin Pharmacol;
61(11): 1493-1504, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34196005
16.
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Cancer Chemother Pharmacol;
88(2): 189-202, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33903938
17.
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.
J Clin Pharmacol;
59(4): 463-471, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30536979
18.
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
J Clin Pharmacol;
59(1): 112-122, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30102413
19.
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
Cancer Chemother Pharmacol;
83(5): 849-858, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30762084
20.
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Clin Pharmacokinet;
58(5): 615-625, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30357650